The Board of Directors and the Chief Executive Officer of SynAct Pharma AB (publ) hereby publish a half-year report for 01/01/2018 – 30/06/2018. The report is available on the company’s and Spotlights Stock Market’s websites (www.synactpharma.com and www.spotlightstockmarket.com). See the enclosed half-yearly report in the press release.
For further information about SynAct Pharma AB, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB
Telephone: +45 28 44 75 67
E-mail: [email protected]
Thomas Jonassen
CSO, SynAct Pharma AB
Telephone: +45 40 15 66 69
E-mail: tj@synactpharma.com
About SynAct Pharma
SynAct Pharma AB conducts research and development into inflammatory diseases. The company has a platform technology based on a new class of drug candidate targeting acute deterioration in chronic inflammatory diseases, with the primary purpose of stimulating natural healing mechanisms.